Skip to main content

Actinium Pharmaceuticals, Inc.

corporate_fare Company Profile

Actinium Pharmaceuticals, Inc.

ATNM·NYSE·Life Sciences·CIK 0001388320

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It uses a biology-driven approach to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies, combining tumor biology and translational medicine expertise with radiochemistry expertise to deliver radioconjugates intended to maximize therapeutic efficacy while minimizing toxicity to healthy tissue. Its pipeline spans early and later-stage development programs in three areas. First, two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential. ATNM-400 targets a novel antigen which does not target PSMA, with demonstrated pre-clinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Second, Actimab-A, which targets myeloid derived suppressor cells (MDSC's) and is also being developed as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in partnership with the National Cancer Institute (NCI); it is being studied in multiple solid tumors in combination with immune checkpoint inhibitors where MDSC's are known to act as an efficacy deterrent for these agents. Third, two targeted conditioning agents: Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its hematology franchise includes Actimab-A, a CD33-targeted therapy, as well as Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents. Both Actimab-A and Iomab-B are Phase 2/3 ready assets and are supported by extensive validation in over 15 clinical trials in which more than 500 patients were treated.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for ATNM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Recent SEC coverage for ATNM spans 10-Q.

Recent high-impact activity:

  • Actinium Q3 Loss Widens to $5.8M; Cash Falls to $28.7M With 12-Month Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$90K
Net Income
-$33.89M
Diluted EPS
-$1.09
Op. Cash Flow
-$24.58M
Free Cash Flow
-$24.68M
Operating Income
-$36.25M
Cash & Equivalents
$48M
Debt / Equity
0.00×
Net Margin
-376.52×
Shares Outstanding
31.2M sh
Source: 10-K · filed 2026-03-30 · accession 0001213900-26-036504

Short Interest & Short Volume

1.69 days to cover

FINRA reported short interest of 593,218 shares in ATNM as of the October 30, 2026 settlement, a 6.0% decrease from the prior period — about 1.7 days to cover at its recent average daily volume. On November 20, 2026, 48.0% of ATNM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)593,218 shares as of October 30, 2026
Change vs prior period▼ 6.0%
Days to cover1.69 at avg daily volume of 351,970
Daily short volume (FINRA facilities)48.0% of 137,986 shares on November 20, 2026
5-day average short volume49.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$1.01 -3.81% today
52-week range · as of 2026-11-16 $0.7351 – $1.72
Market cap
$33.01M
Volume
280.9K (1.1× avg)
3-mo avg 261.3K
Live data · 2026-11-21 11:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ATNM - Latest Insights

ATNM
Nov 16, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.01 info
Change: -$0.1102 (-10%) info
Market Cap: $33.014M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets